top of page

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Clinicaltrials.gov ID

NCT03656536

Status

Recruiting

Study Type

Interventional, Phase 3

Sponsor

Incyte Corporation

Start Date

June 2, 2019

Anticipated End Date

October 25, 2027

Study Contact

Name: Incyte Corporation Call Center (US)

Phone Number:1.855.463.3463

Email: medinfo@incyte.com

About the Study

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Conditions

  • Unresectable Cholangiocarcinoma

  • Metastatic Cholangiocarcinoma

Inclusion/Exclusion Criteria?

Primary, Secondary, Other Outcome Measures??

Locations in Canada

  • Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada (not yet recruiting)

  • Cancercare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada (not yet recruiting)

  • Nova Scotia Health Authority/QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 4K4, Canada

  • Princess Margaret Cancer Center, Toronto, Ontario, MG5 2M9, Canada

  • McGill University Health Centre Research Institute, Montreal, Quebec, H4A 3J1, Canada (not yet recruiting)


Apply Now

About the Study

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Conditions

  • Unresectable Cholangiocarcinoma

  • Metastatic Cholangiocarcinoma

Interventions